Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 February 2021Website:
http://www.sana.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 27 Jun 2024 21:09:15 GMTDividend
Analysts recommendations
Institutional Ownership
SANA Latest News
Additional results from a Sana Biotechnology, Inc. phase 1 study, using SC291 for the treatment of patients with B-cell lymphomas and leukemias, are expected in 2024. Initial results from phase 1 study, using SC291 for the treatment of patients with autoimmune disorders, expected in 2024. Initial results from phase 1 study, using SC262 for the treatment of patients with r/r B-cell Lymphomas who failed prior anti-CD19 therapies, expected in 2024.
SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
Results from the phase 1 study using SC291 for the treatment of patients with B-cell lymphomas are expected to be released later in 2023. It is said that the global B-cell lymphoma treatment market could reach $13.14 billion by 2030. The company is testing the use of its hypoimmune platform, which might be capable of providing long-term durable responses, without immunosuppression being needed.
The average of price targets set by Wall Street analysts indicates a potential upside of 83.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Sana Biotechnology is developing a cell-editing platform that it hopes will be able to avoid immune-system rejection. The company has no revenue but enough cash to fund operations into 2025, it said.
What type of business is Sana Biotechnology?
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
What sector is Sana Biotechnology in?
Sana Biotechnology is in the Healthcare sector
What industry is Sana Biotechnology in?
Sana Biotechnology is in the Biotechnology industry
What country is Sana Biotechnology from?
Sana Biotechnology is headquartered in United States
When did Sana Biotechnology go public?
Sana Biotechnology initial public offering (IPO) was on 04 February 2021
What is Sana Biotechnology website?
https://www.sana.com
Is Sana Biotechnology in the S&P 500?
No, Sana Biotechnology is not included in the S&P 500 index
Is Sana Biotechnology in the NASDAQ 100?
No, Sana Biotechnology is not included in the NASDAQ 100 index
Is Sana Biotechnology in the Dow Jones?
No, Sana Biotechnology is not included in the Dow Jones index
When does Sana Biotechnology report earnings?
The next expected earnings date for Sana Biotechnology is 02 August 2024